Reducing the risk of autoimmune disease

Patent metadata

Field	Value
Publication number	US-9289461-B2
Application number	US-201313839212-A
Country	US
Kind code	B2
Filing date	Mar 15, 2013
Priority date	Mar 15, 2013
Publication date	Mar 22, 2016
Grant date	Mar 22, 2016

Abstract

The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.

First claim

What is claimed is:

1. A method for reducing the risk of type 1 diabetes, treating type 1 diabetes and/or reducing the symptoms of type 1 diabetes, in a subject by administering a composition comprising a casein hydrolysate to the subject, wherein the hydrolysate comprises peptides with a molecular weight of 500 Da to 2000 Da, and wherein the hydrolysate comprises the following peptides: SEQ ID NO. 1, SEQ ID NO. 3, SEQ NO. 4, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 12, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 23, SEQ ID NO. 27, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 35, SEQ ID NO. 39, SEQ ID NO. 40, SEQ ID NO. 44, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 50, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 62, SEQ ID NO. 65, SEQ ID NO. 66, SEQ ID NO. 67, and SEQ ID NO. 68.

2. The method according to claim 1 , wherein the hydrolysate further comprises at least five peptides selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, and SEQ ID NO. 21.

3. The method according to claim 1 , wherein the hydrolysate further comprises at least five peptides selected from the group consisting of SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 36, SEQ ID NO. 37, and SEQ ID NO. 38.

4. The method according to claim 1 , wherein the hydrolysate further comprises at least five peptides selected from the group consisting of SEQ ID NO. 41, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 46, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 53, SEQ ID NO. 54, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 61, SEQ ID NO. 63, and SEQ ID NO. 64.

5. The method according to claim 1 , wherein the hydrolysate is administered in a nutritional composition, comprising a lipid a fat phase, and a protein source.

6. the method according to claim 5 , wherein the nutritional composition comprises about 0.1 to about 1 g/I00 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide.

7. The method according to claim 5 , wherein the nutritional composition further comprises about 5 to 100 mg/I00 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid.

8. The method according to claim 5 , wherein the nutritional composition further comprises arachidonic acid.

9. The method according to claim 1 , wherein the subject is a human child or juvenile.

10. The method according to claim 5 , wherein the nutritional formulation additionally comprises one or more of carbohydrates, nucleic acids, lipids, minerals, anabolic nutrients, vitamins, antioxidants, probiotic bacterial strains and lipotropic agents.

Assignees

• Mead Johnson Nutrition Asia Pacific Pte Ltd
• Mead Johnson Nutrition Co

Inventors

• Hondmann Dirk
• Van Tol Eric A F
• Gross Gabriele
• Schoemaker Marieke H
• Lambers Teartse Tim

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61K38/018 Primary

  from milk · CPC title